Pancreatic cancer and medical history in a population-based case–control study in the San Francisco Bay Area, California

Ko, Andrew H.; Wang, Furong; Holly, Elizabeth A.

doi:10.1007/s10552-007-9024-6

Cited by 44 publications

(33 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The odds ratio (OR) for ovarian cancer was almost doubled in participants with a history of hyperthyroidism (OR 1.8, adjusted for age, pregnancies, race, oral contraceptive use, hysterectomy, and familial history of ovarian cancer) (Ness et al 2000). In a similar study on risks for pancreatic cancer, a history of hyperthyroidism was associated with a twofold increased risk (OR 2.1, adjusted for race, education, BMI, smoking, and history of diabetes) (Ko et al 2007). While these retrospective studies indicated an increased cancer risk with higher TH levels, their results depended on selfreported thyroid disorders and thyroid function tests were not analyzed.…”

Section: Epidemiology Suggests Tumor-promoting Effects Of Thmentioning

confidence: 97%

Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective

Moeller¹,

Führer²

2013

Endocrine-Related Cancer

157

138

View full text Add to dashboard Cite

Thyroid hormones (THs) may play a role in diseases other than hyper-and hypothyroidism. Several lines of evidence suggest tumor-promoting effects of TH and TH receptors. They are possibly mediated by phosphatidylinositol-3-kinase and MAPK and involve among others stimulation of angiogenesis via avb3. Thus, an increased risk for colon, lung, prostate, and breast cancer with lower TSH has been demonstrated in epidemiological studies, even suggesting a TH dose effect on cancer occurrence. Furthermore, higher TH levels were associated with an advanced clinical stage of breast and prostate cancer. In rodent models, TH stimulated growth and metastasis of tumor transplants, whereas hypothyroidism had opposite effects. In clinical studies of glioblastoma and head and neck cancer, hypothyroid patients showed longer survival than euthyroid patients. Also, patients with renal cell cancer that were treated with the tyrosine kinase inhibitor sunitinib and developed hypothyroidism in due course showed significantly longer survival than patients that remained euthyroid. Development of hypothyroidism was an independent predictor for survival in two studies. Yet, it is still possible that hypothyroidism is only a surrogate marker for treatment efficacy and does not positively influence treatment outcome by itself. Future cancer treatment studies, especially with substances that can induce hypothyroidism, should therefore be designed in a way that allows for an analysis of thyroid function status and its contribution on treatment outcome.

show abstract

Section: Epidemiology Suggests Tumor-promoting Effects Of Thmentioning

confidence: 97%

Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective

Moeller¹,

Führer²

2013

Endocrine-Related Cancer

157

138

View full text Add to dashboard Cite

show abstract

“…Indeed, conflicting results are reported. Population-based case-control studies of risk factors associated to development of ovarian and pancreatic cancers found that hyperthyroidism is associated with a two-fold increase in cancer risk (Ness et al 2000, Ko et al 2007. Moreover, while hyperthyroidism is associated with more advanced clinical stage and higher risk of recurrence in prostate cancer (Lehrer et al 2002), hypothyroidism is associated with a lower risk of carcinoma and a reduced progression to more invasive stages for mammary cancer (Cristofanilli et al 2005).…”

Section: Trs Hypo-and Hyperthyroidism and Hccmentioning

confidence: 99%

T3/TRs axis in hepatocellular carcinoma: new concepts for an old pair

Perra

Plateroti

Columbano

2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and its burden is expected to further increase in the next years. Chronic inflammation, induced by multiple viruses or metabolic alterations, and epigenetic and genetic modifications, cooperate in cancer development via a combination of common and distinct aetiology-specific pathways. In spite of the advances of classical therapies, the prognosis of this neoplasm has not considerably improved over the past few years. The advent of targeted therapies and the approval of the systemic treatment of advanced HCC with the kinase inhibitor sorafenib have provided some hope for the future. However, the benefits obtained from this treatment are still disappointing, as it extends the median life expectancy of patients by only few months. It is thus mandatory to find alternative effective treatments. Although the role played by thyroid hormones (THs) and their nuclear receptors (TRs) in human cancer is still unclear, mounting evidence indicates that they behave as oncosuppressors in HCC. However, the molecular mechanisms by which they exert this effect and the consequence of their activation following ligand binding on HCC progression remain elusive. In this review, we re-evaluate the existing evidence of the role of TH/TRs in HCC development; we will also discuss how TR alterations could affect fundamental biological processes, such as hepatocyte proliferation and differentiation, and consequently HCC progression. Finally, we will discuss if and how TRs can be foreseen as therapeutic targets in HCC and whether selective TR modulation by TH analogues may hold promise for HCC treatment.

show abstract

“…Of these, cigarette smoking has been regarded as the most important risk factor. Smokers have 2-fold to 3-fold increased risk of PC compared to non-smokers with cigarette smoking accounting for approximately a quarter of PC incidence Silverman et al, 1994;Fuchs et al, 1996;Lowenfels et al, 2006;Ko et al, 2007;Bao et al, 2009;Talamini et al, 2010;Nitsche et al, 2011). Hereditary PC accounts for 5%-10% of all cases.…”

Section: Introductionmentioning

confidence: 99%

“…Hereditary PC accounts for 5%-10% of all cases. Individuals with family history of PC, especially have first-degree relative(s) with PC, were consistently been found to be associated with added risk, and risk raised as the number of affected first-degree relative increased (Falk et al, 1998;Brentnall et al, 1999;Klein et al, 2004;Ko et al, 2007;Permuth-Wey et al, 2009). …”

Section: Introductionmentioning

confidence: 99%

Association Between Pancreatitis and Subsequent Risk of Pancreatic Cancer: a Systematic Review of Epidemiological Studies

Tong¹,

Geng²,

Chai³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

This study aimed to summarize published epidemiological evidence for the relationship between pancreatitis and subsequent risk of pancreatic cancer (PC). We searched Medline and Embase for epidemiological studies published by February 5 th , 2014 examining the risk of PC in pancreatitis patients using highly inclusive algorithms. Information about first author, year of publication, country of study, recruitment period, type of pancreatitis, study design, sample size, source of controls and attained age of subjects were extracted by two researchers and Stata 11.0 was used to perform the statistical analyses and examine publication bias. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated with the random effects model. A total of 17 articles documenting 3 cohort and 14 case-control studies containing 14,667 PC cases and 17,587 pancreatitis cases were included in this study. The pooled OR between pancreatitis and PC risk was 7.05 (95%CI: 6.42-7.75). Howeever, the pooled ORs of case-control and cohort studies were 4.62 (95%CI: 4.08-5.22) and 16.3 (95%CI: 14.3-18.6) respectively. The risk of PC was the highest in patients with chronic pancreatitis (pooled OR=10.35; 95%CI: 9.13-11.75), followed by unspecified type of pancreatitis (pooled OR=6.41; 95%CI: 4.93-8.34), both acute and chronic pancreatitis (pooled OR=6.13; 95%CI: 5.00-7.52), and acute pancreatitis (pooled OR=2.12; 95%CI: 1.59-2.83). The pooled OR of PC in pancreatitis cases diagnosed within 1 year was the highest (pooled OR=23.3; 95%CI: 14.0-38.9); and the risk in subjects diagnosed with pancreatitis for no less than 2, 5 and 10 years were 3.03 (95%CI: 2.41-3.81), 2.82 (95%CI: 2.12-3.76) and 2.25 (95%CI: 1.59-3.19) respectively. Pancreatitis, especially chronic pancreatitis, was associated with a significantly increased risk of PC; and the risk decreased with increasing duration since diagnosis of pancreatitis.

show abstract

Pancreatic cancer and medical history in a population-based case–control study in the San Francisco Bay Area, California

Abstract: History of recent gallbladder conditions, gastric and/or duodenal ulcers may represent an early manifestation of pancreatic cancer rather than an independent risk factor. These results warrant further investigation in pooled analyses.

Cited by 44 publications

References 67 publications

Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective

Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective

T3/TRs axis in hepatocellular carcinoma: new concepts for an old pair

Association Between Pancreatitis and Subsequent Risk of Pancreatic Cancer: a Systematic Review of Epidemiological Studies

Contact Info

Product

Resources

About